A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)

November 5, 2022 | American Society of Nephrology (ASN) Kidney Week

Rizk, et. al.

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Patients with Immunoglobulin A Nephropathy (IgAN)

Dana V Rizk, Vlado Perkovic, Richard Lafayette, Hernan Trimarchi, Jonathan Barratt, Kevin Caroll, Vladimir Tesar, Hong Zhang, Yusuke Suzuki, Adrian Liew, Muh Geot Wong, Bruce Leslie, Mohit Mathur, Jeffrey Hafkin

>SEE POSTER